Clinical success and quality of life with brimonidine 0.2% or Timolol 0.5% used twice daily in glaucoma or ocular hypertension

A randomized clinical trial

J. C. Javitt, R. M. Schiffman, W. Atlas, K. J. Baum, D. L. Cookem, H. B. DuBiner, Joanne Katz, T. Kupin, J. E. Memmen, T. K. Mundorf, E. Nelson, H. Offenberg, H. I. Schenker, E. Sharpe, D. Stevenson, W. C. Stewart, N. Tanchel, R. Whitaker

Research output: Contribution to journalArticle

Abstract

Purpose: To compare the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients naive to glaucoma therapy. Methods: A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2% were compared with those of timolol maleate 0.5% in patients with glaucoma and ocular hypertension was conducted. Two hundred nineteen patients were enrolled - 111 in the brimonidine group and 108 in the timolol group. Patients instilled their study medications twice daily for 4 months. Factors for determining clinical success were reduction of intraocular pressure (IOP), safety, and adverse events. Quality of life effects were assessed with the SF-36 Health Survey and Glaucoma Disability Index questionnaires. Results: Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment. The overall mean decrease in lOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol. Few patients reported a specific adverse event and, with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences. No significant chronotropic effects on the heart were seen with brimonidine, while small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol. Mean systolic and diastolic blood pressure remained relatively stable in both groups. Quality of life remained stable, with no significant between-group differences. Conclusions: As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart. Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.

Original languageEnglish (US)
Pages (from-to)224-234
Number of pages11
JournalJournal of Glaucoma
Volume9
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Timolol
Ocular Hypertension
Glaucoma
Randomized Controlled Trials
Quality of Life
Blood Pressure
Brimonidine Tartrate
Therapeutics
Health Surveys
Intraocular Pressure
Heart Rate
Clinical Trials
Safety

Keywords

  • Alphagan
  • Brimonidine
  • Clinical effectiveness
  • Glaucoma Disability Index
  • Quality of life
  • Timolol
  • Timoptic

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Javitt, J. C., Schiffman, R. M., Atlas, W., Baum, K. J., Cookem, D. L., DuBiner, H. B., ... Whitaker, R. (2000). Clinical success and quality of life with brimonidine 0.2% or Timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical trial. Journal of Glaucoma, 9(3), 224-234.

Clinical success and quality of life with brimonidine 0.2% or Timolol 0.5% used twice daily in glaucoma or ocular hypertension : A randomized clinical trial. / Javitt, J. C.; Schiffman, R. M.; Atlas, W.; Baum, K. J.; Cookem, D. L.; DuBiner, H. B.; Katz, Joanne; Kupin, T.; Memmen, J. E.; Mundorf, T. K.; Nelson, E.; Offenberg, H.; Schenker, H. I.; Sharpe, E.; Stevenson, D.; Stewart, W. C.; Tanchel, N.; Whitaker, R.

In: Journal of Glaucoma, Vol. 9, No. 3, 2000, p. 224-234.

Research output: Contribution to journalArticle

Javitt, JC, Schiffman, RM, Atlas, W, Baum, KJ, Cookem, DL, DuBiner, HB, Katz, J, Kupin, T, Memmen, JE, Mundorf, TK, Nelson, E, Offenberg, H, Schenker, HI, Sharpe, E, Stevenson, D, Stewart, WC, Tanchel, N & Whitaker, R 2000, 'Clinical success and quality of life with brimonidine 0.2% or Timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical trial', Journal of Glaucoma, vol. 9, no. 3, pp. 224-234.
Javitt, J. C. ; Schiffman, R. M. ; Atlas, W. ; Baum, K. J. ; Cookem, D. L. ; DuBiner, H. B. ; Katz, Joanne ; Kupin, T. ; Memmen, J. E. ; Mundorf, T. K. ; Nelson, E. ; Offenberg, H. ; Schenker, H. I. ; Sharpe, E. ; Stevenson, D. ; Stewart, W. C. ; Tanchel, N. ; Whitaker, R. / Clinical success and quality of life with brimonidine 0.2% or Timolol 0.5% used twice daily in glaucoma or ocular hypertension : A randomized clinical trial. In: Journal of Glaucoma. 2000 ; Vol. 9, No. 3. pp. 224-234.
@article{3bf88a0eb6d5400d89c37adb256d3462,
title = "Clinical success and quality of life with brimonidine 0.2{\%} or Timolol 0.5{\%} used twice daily in glaucoma or ocular hypertension: A randomized clinical trial",
abstract = "Purpose: To compare the clinical success rates and quality of life impact of brimonidine 0.2{\%} with timolol 0.5{\%} in newly diagnosed patients naive to glaucoma therapy. Methods: A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2{\%} were compared with those of timolol maleate 0.5{\%} in patients with glaucoma and ocular hypertension was conducted. Two hundred nineteen patients were enrolled - 111 in the brimonidine group and 108 in the timolol group. Patients instilled their study medications twice daily for 4 months. Factors for determining clinical success were reduction of intraocular pressure (IOP), safety, and adverse events. Quality of life effects were assessed with the SF-36 Health Survey and Glaucoma Disability Index questionnaires. Results: Clinical success was 71{\%} (75/106) with brimonidine and 70{\%} (73/105) with timolol as initial treatment. The overall mean decrease in lOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol. Few patients reported a specific adverse event and, with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences. No significant chronotropic effects on the heart were seen with brimonidine, while small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol. Mean systolic and diastolic blood pressure remained relatively stable in both groups. Quality of life remained stable, with no significant between-group differences. Conclusions: As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart. Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.",
keywords = "Alphagan, Brimonidine, Clinical effectiveness, Glaucoma Disability Index, Quality of life, Timolol, Timoptic",
author = "Javitt, {J. C.} and Schiffman, {R. M.} and W. Atlas and Baum, {K. J.} and Cookem, {D. L.} and DuBiner, {H. B.} and Joanne Katz and T. Kupin and Memmen, {J. E.} and Mundorf, {T. K.} and E. Nelson and H. Offenberg and Schenker, {H. I.} and E. Sharpe and D. Stevenson and Stewart, {W. C.} and N. Tanchel and R. Whitaker",
year = "2000",
language = "English (US)",
volume = "9",
pages = "224--234",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clinical success and quality of life with brimonidine 0.2% or Timolol 0.5% used twice daily in glaucoma or ocular hypertension

T2 - A randomized clinical trial

AU - Javitt, J. C.

AU - Schiffman, R. M.

AU - Atlas, W.

AU - Baum, K. J.

AU - Cookem, D. L.

AU - DuBiner, H. B.

AU - Katz, Joanne

AU - Kupin, T.

AU - Memmen, J. E.

AU - Mundorf, T. K.

AU - Nelson, E.

AU - Offenberg, H.

AU - Schenker, H. I.

AU - Sharpe, E.

AU - Stevenson, D.

AU - Stewart, W. C.

AU - Tanchel, N.

AU - Whitaker, R.

PY - 2000

Y1 - 2000

N2 - Purpose: To compare the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients naive to glaucoma therapy. Methods: A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2% were compared with those of timolol maleate 0.5% in patients with glaucoma and ocular hypertension was conducted. Two hundred nineteen patients were enrolled - 111 in the brimonidine group and 108 in the timolol group. Patients instilled their study medications twice daily for 4 months. Factors for determining clinical success were reduction of intraocular pressure (IOP), safety, and adverse events. Quality of life effects were assessed with the SF-36 Health Survey and Glaucoma Disability Index questionnaires. Results: Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment. The overall mean decrease in lOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol. Few patients reported a specific adverse event and, with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences. No significant chronotropic effects on the heart were seen with brimonidine, while small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol. Mean systolic and diastolic blood pressure remained relatively stable in both groups. Quality of life remained stable, with no significant between-group differences. Conclusions: As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart. Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.

AB - Purpose: To compare the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients naive to glaucoma therapy. Methods: A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2% were compared with those of timolol maleate 0.5% in patients with glaucoma and ocular hypertension was conducted. Two hundred nineteen patients were enrolled - 111 in the brimonidine group and 108 in the timolol group. Patients instilled their study medications twice daily for 4 months. Factors for determining clinical success were reduction of intraocular pressure (IOP), safety, and adverse events. Quality of life effects were assessed with the SF-36 Health Survey and Glaucoma Disability Index questionnaires. Results: Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment. The overall mean decrease in lOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol. Few patients reported a specific adverse event and, with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences. No significant chronotropic effects on the heart were seen with brimonidine, while small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol. Mean systolic and diastolic blood pressure remained relatively stable in both groups. Quality of life remained stable, with no significant between-group differences. Conclusions: As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart. Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.

KW - Alphagan

KW - Brimonidine

KW - Clinical effectiveness

KW - Glaucoma Disability Index

KW - Quality of life

KW - Timolol

KW - Timoptic

UR - http://www.scopus.com/inward/record.url?scp=0034445222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034445222&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 224

EP - 234

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 3

ER -